5-trans U-46619
(Synonyms: 5,6-trans U-46619) 目录号 : GC17719
An isomer of U-46619
Cas No.:330796-58-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
5-trans U-46619 is a minor impurity (2-5%) which variably exists in most commercial preparations of U-46619 [1]. U-46619 is a selective thromboxane A2 agonist involved in inducing platelet aggregation and vascular smooth muscle contraction [2].
The biological activity of 5-trans U-46619 has been rarely tested separately from U-46619 itself. In the only case published to date, 5-trans U-46619 was found to be a about half as potent an inhibitor of Prostaglandin E synthase as the 5-cis version of U-46619 [1]. Thromboxane A2 (TxA2) has been involved in the pathogenesis of airway hyperresponsiveness. TXA2 is a type of thromboxane produced by activated platelets and shows prothrombotic properties. Thromboxane A2 has also been known as a vasoconstrictor and is especially important during tissue injury and inflammation [3].
References:
[1] Quraishi O, Mancini J A, Riendeau D. Inhibition of inducible prostaglandin E 2 synthase by 15-deoxy-Δ 12, 14-prostaglandin J 2 and polyunsaturated fatty acids[J]. Biochemical pharmacology, 2002, 63(6): 1183-1189.
[2] Coleman, R. A.,Humphrey, P.P.A.,Kennedy, I., et al. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. British Journal of Pharmacology 73, 773-778 (1981).
[3] Svensson J, Strandberg K, Tuvemo T, et al. Thromboxane A2: Effects of airway and vascular smooth muscle[J]. Prostaglandins, 1977, 14(3): 425-436.
| Cas No. | 330796-58-2 | SDF | |
| 别名 | 5,6-trans U-46619 | ||
| 化学名 | 9,11-dideoxy-9α,11α-methanoepoxy-prosta-5E,13E-dien-1-oic acid | ||
| Canonical SMILES | CCCCC[C@H](O)/C=C/[C@H]1C2OCC(C2)[C@@H]1C/C=C/CCCC(O)=O | ||
| 分子式 | C21H34O4 | 分子量 | 350.5 |
| 溶解度 | ≤100mg/ml in ethanol;100mg/ml in DMSO;100mg/ml in dimethyl formamide;2mg/ml in PBS(pH7.2) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8531 mL | 14.2653 mL | 28.5307 mL |
| 5 mM | 0.5706 mL | 2.8531 mL | 5.7061 mL |
| 10 mM | 0.2853 mL | 1.4265 mL | 2.8531 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet